Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finance]
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $250.00 price target on the stock.